Contact & Map

Company Staff Services Performance Quality Issues Why M.A.R.C.O. Jobs Partner


Propofol anesthesia in spontaneously breathing children undergoing magnetic resonance imaging: Comparison of two propofol emulsions.
Gutmann A., Pessenbacher K., Gschanes A., Eggenreich U., Wargenau M.,
Toller W.
Paediatr Anesthesia 2006; 16(3): 266-274

Pharmacokinetics of the generic formulation propofol 1% Fresenius in comparison with the original formulation (Disoprivan® 1%).
Jungheinrich C., Scharpf R., Wargenau M., Dilger C., Bepperling F.
Clin Drug Invest 2002; 22(7): 417-427

The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild to severe renal impairment.
Jungheinrich C., Scharpf R., Wargenau M., Bepperling F., Baron JF.
Anesth Analg 2002; 95 (3): 544-51

Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union.
Schug BS., Brendel E., Wolf D., Wonnemann M., Wargenau M., Blume HH.
Eur J Pharm Sci 2002; 15(3): 279-85

Dosage form related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast.
Schug BS., Brendel E., Wonnemann M., Wolf D., Wargenau M., Dingler A.,
Blume HH.
Eur J Clin Pharmacol 2002; 58(2): 119-25

Dose finding strategies involving interim analysis and unbalanced treatment allocation.
Wargenau M.
Statistics in Medicine 1995 May; 15-30; 14 (9-10); 901-7; discussion 909.

Planning of drug interaction studies involving digoxin treatment: A statistical view. Collie H., Wargenau M.
Int. J. Clin. Pharmacol Ther Toxicol 1992; 30 (11): 534-6 Review.

Poster Presentations

Influence of ketoconazole on the pharmacokinetic and safety of intravenous Iclaprim.
Hadvary P., Neuenhofer D., Brandt R., Ullmann U., Wargenau M., Thomsen T., Islam K.
9th Annual Congress of the German Association of the Clinical Pharmacology, Kiel, 1.-3. Nov. 2007
Basic & Clinical Pharmacology & Toxicology 101 (5): 359-389

Evaluation of effect of Iclaprim on the QT interval in healthy volunteers
Hadvary P., Leighton A., Wargenau M., Thomsen T., Islam K.
45th Annual Meeting of IDSA, San Diego , 4.-7. Oct. 2007

Body temperature after treatment with esmirtazapine in healthy volunteers.
de Kam PJ., Bursi R., Kerbusch T., Brunnert M., Ivgy-May N., Peeters PAM.
8th Congress of the European Association for Clinical Pharmacology and Therapeutics, Amsterdam, Aug. 2007
Basic & Clinical Pharmacology & Toxicology 101 (S1): 51-102

Pharmacokinetics and tolerability of intravenous infusion of the new hydroxyethyl starch 130/0,4 (6%) in 19 subjects with mild to severe renal impairment: Terminal half life and peak concentration (Cmax) remain unaffected.
Jungheinrich C., Scharpf R., Wargenau M., Bepperling F.
Critical Care, 5 Suppl 1 (2001), 21st International Symposium on Intensiv Care and Emergency Medicine.

Pharmacokinetics and tolerability of a new hydroxyethyl starch specification 6% HES 130/0.4 (Voluven®) after single-dose infusion in subjects with renal impairment.
Eckl KM., Jungheinrich C., Scharpf R., Bepperling F., Wargenau M.
Deutscher Anästhesiekongress - DAK International 06.-09.May 2000